ALLO

Allogene Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of next-generation allogeneic T-cell therapies designed to target various forms of cancer. Leveraging its proprietary technology platform, Allogene aims to deliver transformative immuno-oncology treatments that enhance the body’s natural ability to fight cancer while minimizing associated treatment risks and complexities. With a strong pipeline of candidates and a dedicated focus on advancing therapeutic solutions, Allogene is positioned to significantly impact the oncology landscape.